Home Featured Page 174

Featured

Latest

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Small Pharma Reports Fiscal Third Quarter 2021 Highlights

IntelGenx Receives Third Loan Tranche from atai

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results...

Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares...

Numinus Appoints New Bioscience Advisors to Advance IP Development

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status...

Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for...

Psychedelic or Not: Of Mice, 5-HT2A Agonists, and Head Shakes

PT289 – Payton Nyquvest – Shifting the Mindset on Pain, Psychedelics,...

1...173174175...291 Page 174 of 291

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Small Pharma Reports Fiscal Third Quarter 2021 Highlights

IntelGenx Receives Third Loan Tranche from atai

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results...

Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares...

Numinus Appoints New Bioscience Advisors to Advance IP Development

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status...

Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for...

Psychedelic or Not: Of Mice, 5-HT2A Agonists, and Head Shakes

PT289 – Payton Nyquvest – Shifting the Mindset on Pain, Psychedelics,...

EDITOR PICKS

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY